Deciphera Pharmaceuticals Management
Management criteria checks 4/4
Deciphera Pharmaceuticals' CEO is Steve Hoerter, appointed in Mar 2019, has a tenure of 5.08 years. total yearly compensation is $3.55M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 0.089% of the company’s shares, worth $1.06M. The average tenure of the management team and the board of directors is 4.2 years and 8.8 years respectively.
Key information
Steve Hoerter
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 19.8% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.09% |
| Management average tenure | 4.2yrs |
| Board average tenure | 8.8yrs |
Recent management updates
Recent updates
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%
Feb 11
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Feb 05Deciphera to expand geographic reach and clinical potential of ripretinib
Jan 11Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 72% Above Its Share Price
Dec 15Deciphera completes enrollment in late-stage study of ripretinib in GIST patients
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$195m |
| Sep 30 2023 | n/a | n/a | -US$194m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$182m |
| Dec 31 2022 | US$4m | US$703k | -US$179m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$258m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$9m | US$676k | -US$300m |
| Sep 30 2021 | n/a | n/a | -US$274m |
| Jun 30 2021 | n/a | n/a | -US$258m |
| Mar 31 2021 | n/a | n/a | -US$255m |
| Dec 31 2020 | US$8m | US$650k | -US$266m |
| Sep 30 2020 | n/a | n/a | -US$271m |
| Jun 30 2020 | n/a | n/a | -US$263m |
| Mar 31 2020 | n/a | n/a | -US$218m |
| Dec 31 2019 | US$9m | US$435k | -US$192m |
| Sep 30 2019 | n/a | n/a | -US$157m |
| Jun 30 2019 | n/a | n/a | -US$126m |
| Mar 31 2019 | n/a | n/a | -US$126m |
| Dec 31 2018 | US$447k | n/a | -US$100m |
Compensation vs Market: Steve's total compensation ($USD3.55M) is about average for companies of similar size in the US market ($USD3.47M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Hoerter (52 yo)
5.1yrs
Tenure
US$3,554,485
Compensation
Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.1yrs | US$3.55m | 0.089% $ 1.1m | |
| Executive VP | 9.2yrs | US$1.41m | 0.052% $ 619.3k | |
| Senior VP & Chief Commercial Officer | 5.6yrs | US$1.13m | 0.038% $ 456.7k | |
| Executive VP & Chief Medical Officer | 4.5yrs | US$1.49m | 0.088% $ 1.1m | |
| Senior VP & Chief Technical Officer | less than a year | no data | no data | |
| Executive VP & Chief Scientific Officer | less than a year | no data | 0% $ 0 | |
| Senior Vice President of Finance & Investor Relations | no data | no data | no data | |
| Senior VP & General Counsel | 5.1yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 2.3yrs | no data | no data | |
| Senior VP & Chief Development Officer | 4.2yrs | no data | 0.042% $ 499.3k | |
| Senior VP & Head of International | 3.2yrs | no data | no data | |
| Senior Vice President of Clinical Development | 3.3yrs | no data | no data |
4.2yrs
Average Tenure
52yo
Average Age
Experienced Management: DCPH's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.9yrs | US$3.55m | 0.089% $ 1.1m | |
| Independent Director | 9.2yrs | US$237.06k | 0% $ 0 | |
| Independent Director | 7.5yrs | US$242.06k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$244.57k | 0% $ 0 | |
| Independent Chairman | 4.3yrs | US$237.07k | 0% $ 0 | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Independent Director | 16.7yrs | US$273.32k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Independent Director | 9.2yrs | US$234.57k | 0.013% $ 160.4k | |
| Member of Scientific Advisory Board | no data | no data | no data |
8.8yrs
Average Tenure
61yo
Average Age
Experienced Board: DCPH's board of directors are considered experienced (8.8 years average tenure).